Table 1. Characteristics of 329 Patients with Rectal Cancer Treated with NCRT.
| Total (%) | P | |
|---|---|---|
| Age | 0.6952 | |
| ≤ 60 | 232 (70.5) | |
| > 60 | 97 (29.5) | |
| Gender | 0.9285 | |
| Male | 226 (68.7) | |
| Female | 103 (31.3) | |
| Distance from the anal verge | 0.1139 | |
| ≥ 5 cm | 91 (27.7) | |
| < 5 cm | 238 (72.3) | |
| Surgical Procedure | 0.6505 | |
| LAR | 138 (41.9) | |
| APR | 170 (51.7) | |
| Hartmann resection | 21 (6.4) | |
| Clinical T stage | 0.6185 | |
| cT3 | 221 (67.2) | |
| cT4 | 108 (32.8) | |
| Clinical N stage | 0.4734 | |
| cN0 | 64 (19.5) | |
| cN+ | 265 (80.5) | |
| Interval completion of NCRT to surgery | 0.1187 | |
| ≥ 7 weeks | 177 (46.2) | |
| < 7 weeks | 152 (53.8) | |
| Concurrent chemotherapy | ||
| Capecitabine | 136 (41.3) | 0.5056 |
| Capecitabine plus oxaliplatin | 193 (58.7) | |
| Adjuvant chemotherapy | 0.4651 | |
| Yes | 157 (47.7) | |
| No | 172 (52.3) | |
| ypTNM | <0.0001 | |
| 0 | 41 (12.5) | |
| I | 54 (16.4) | |
| II | 99 (30.1) | |
| III | 135 (41.0) | |
| Follow-up | - | |
| Local recurrence | 8 (2.4) | |
| Systematic recurrence | 80 (24.3) | |
| Local and systematic recurrence | 5 (1.5) | |
Abbreviations: LAR, low anterior resection; APR, abdominoperineal resection; NCRT, neoadjuvant chemoradiotherapy. P value was calculated by Kaplan-Meier survival analysis correlated with 3-year DFS.